Safety and Risk of Major Complications With Diagnostic Cardiac Catheterization.


Journal

Circulation. Cardiovascular interventions
ISSN: 1941-7632
Titre abrégé: Circ Cardiovasc Interv
Pays: United States
ID NLM: 101499602

Informations de publication

Date de publication:
07 2019
Historique:
entrez: 10 7 2019
pubmed: 10 7 2019
medline: 27 5 2020
Statut: ppublish

Résumé

We aim to study the incidence of major complications related to procedure defined as in-hospital death, myocardial infarction, stroke, pericardial effusion or tamponade, percutaneous coronary intervention due to iatrogenic coronary dissection, or unplanned bypass surgery within 72 hours after diagnostic left heart catheterization (LHC; primary end point). Furthermore, all causes of in-hospital death after LHC were adjudicated and reported (secondary end point). Diagnostic LHC procedures (aortic angiography; coronary, including graft, angiography; and left ventricular angiography) from January 1, 2002, through December 31, 2013, were identified using the clinical scheduling system at Mayo Clinic, Rochester, and complications were identified through electronic records. International Classification of Diseases, Ninth Revision billing codes were used. Registration was queried to identify all-cause mortality. All events were reviewed and adjudicated. There were 43 786 diagnostic LHC procedures; 97.3% were coronary angiograms. The mean age of patients was 64.5 years (13.6), and the majority were male (61.5%). Primary end point was seen in 36 (0.082%) procedures or 8.2 of 10 000 LHCs. Combined right sided procedures with LHC did not increase the risk of major complications. Cardiogenic and septic shock, cardiac arrhythmia, and postsurgical complication were the most common causes of in-hospital death after LHC. The overall rates of major complications related to diagnostic cardiac catheterization procedures are extremely rare. The majority of the deaths occurring post-diagnostic LHC procedures were secondary to acute illness rather than directly related to diagnostic procedure.

Sections du résumé

BACKGROUND
We aim to study the incidence of major complications related to procedure defined as in-hospital death, myocardial infarction, stroke, pericardial effusion or tamponade, percutaneous coronary intervention due to iatrogenic coronary dissection, or unplanned bypass surgery within 72 hours after diagnostic left heart catheterization (LHC; primary end point). Furthermore, all causes of in-hospital death after LHC were adjudicated and reported (secondary end point).
METHODS AND RESULTS
Diagnostic LHC procedures (aortic angiography; coronary, including graft, angiography; and left ventricular angiography) from January 1, 2002, through December 31, 2013, were identified using the clinical scheduling system at Mayo Clinic, Rochester, and complications were identified through electronic records. International Classification of Diseases, Ninth Revision billing codes were used. Registration was queried to identify all-cause mortality. All events were reviewed and adjudicated. There were 43 786 diagnostic LHC procedures; 97.3% were coronary angiograms. The mean age of patients was 64.5 years (13.6), and the majority were male (61.5%). Primary end point was seen in 36 (0.082%) procedures or 8.2 of 10 000 LHCs. Combined right sided procedures with LHC did not increase the risk of major complications. Cardiogenic and septic shock, cardiac arrhythmia, and postsurgical complication were the most common causes of in-hospital death after LHC.
CONCLUSIONS
The overall rates of major complications related to diagnostic cardiac catheterization procedures are extremely rare. The majority of the deaths occurring post-diagnostic LHC procedures were secondary to acute illness rather than directly related to diagnostic procedure.

Identifiants

pubmed: 31284736
doi: 10.1161/CIRCINTERVENTIONS.119.007791
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e007791

Auteurs

Mohammed A Al-Hijji (MA)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Ryan J Lennon (RJ)

Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, MN(R.J.L., D.C.).

Rajiv Gulati (R)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Abdallah El Sabbagh (A)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Jae Yoon Park (JY)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Daniel Crusan (D)

Division of Biomedical Statistics and Informatics, Mayo Clinic and Mayo Foundation, Rochester, MN(R.J.L., D.C.).

Amrit Kanwar (A)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Atta Behfar (A)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Amir Lerman (A)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

David R Holmes (DR)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Malcolm Bell (M)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Mandeep Singh (M)

Division of Cardiovascular Medicine, Mayo Clinic and Mayo Foundation, Rochester, MN (M.A.A.-H., R.G., A.E.S., J.Y.P., A.K., A.B., A.L., D.R.H., M.B., M.S.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH